Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma.

Auel, Britta; Goldschmidt, Hartmut; Geer, Thomas; Moehler, Thomas M; Platzbecker, Uwe; Naumann, Ralph; Blau, Igor; Hänel, Mathias; Knauf, Wolfgang; Nückel, Holger; Salwender, Hans-Jürgen; Scheid, Christof; Weisel, Katja; Gorschlüter, Marcus; Glasmacher, Axel; Schmidt-Wolf, Ingo G H

Auel, Britta; Goldschmidt, Hartmut; Geer, Thomas; Moehler, Thomas M; Platzbecker, Uwe; Naumann, Ralph; Blau, Igor; Hänel, Mathias; Knauf, Wolfgang; Nückel, Holger; Salwender, Hans-Jürgen; Scheid, Christof; Weisel, Katja; Gorschlüter, Marcus; Glasmacher, Axel; Schmidt-Wolf, Ingo G H.

Afiliação

Auel B; Department of Internal Medicine III, Center for Integrated Oncology (CIO), University Hospital Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany.

Indian J Hematol Blood Transfus ; 28(2): 67-76, 2012 Jun.

Article em En | MEDLINE | ID: mdl-23730012

Palavras-chave

Blood Transfusion Medicine; Dexamethasone; Hematology; Human Genetics; Idarubicin; Medicine & Public Health; Myeloma; Oncology; Thalidomide; Vinorelbine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2012 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2012 Tipo de documento: Article